Skip to main content
Atrás
WILYY logo

Demant A/S

Calidad de datos: 100%
WILYY
OTC Healthcare Medical - Devices
$13.45
$0.00 (0.00%)
Cap. Mercado: 5.93B
También listada como WILLF OTC
Rango del Día
$13.45 $14.49
Rango de 52 Semanas
$13.45 $21.93
Volumen
1
Promedio 50D / 200D
$15.24 / $17.81
Cierre Anterior
$13.45

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E 3.8 0.4
P/B 0.6 2.9
ROE % 15.9 3.8
Net Margin % 6.7 3.9
Rev Growth 5Y % 6.4 10.0
D/E 2.1 0.2

Precio Objetivo de Analistas

No hay cobertura de analistas disponible

Estimaciones de Ganancias

Período EPS Est. Ingresos Est. Analistas
FY2027 $0.00
$0.00 – $0.00
 27 B 0
FY2026 $7.37
$7.27 – $7.63
 25 B 1

Puntos Clave

Revenue grew 6.43% annually over 5 years — modest growth
Earnings declined -35.27% over the past year
ROE of 15.92% — decent returns on equity
Debt/Equity of 2.13 — high leverage
Generating 3.18B in free cash flow
P/E of 3.84 — trading at a low valuation

Crecimiento

Revenue Growth (5Y)
6.43%
Revenue (1Y)2.46%
Earnings (1Y)-35.27%
FCF Growth (3Y)-5.86%

Calidad

Return on Equity
15.92%
ROIC9.51%
Net Margin6.73%
Op. Margin17.01%

Seguridad

Debt / Equity
2.13
Current Ratio1.36
Interest Coverage7.35

Valoración

P/E Ratio
3.84
P/B Ratio0.60
EV/EBITDA6.55
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 2.46% Revenue Growth (3Y) 1.17%
Earnings Growth (1Y) -35.27% Earnings Growth (3Y) -7.22%
Revenue Growth (5Y) 6.43% Earnings Growth (5Y) -11.45%
Profitability
Revenue (TTM) 22.97B Net Income (TTM) 1.55B
ROE 15.92% ROA 3.95%
Gross Margin 75.62% Operating Margin 17.01%
Net Margin 6.73% Free Cash Flow (TTM) 3.18B
ROIC 9.51% FCF Growth (3Y) -5.86%
Safety
Debt / Equity 2.13 Current Ratio 1.36
Interest Coverage 7.35 Dividend Yield 0.00%
Valuation
P/E Ratio 3.84 P/B Ratio 0.60
P/S Ratio 0.26 PEG Ratio -0.80
EV/EBITDA 6.55 Dividend Yield 0.00%
Market Cap 5.93B Enterprise Value 25.59B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 22.97B 22.42B 22.44B 19.71B 17.91B
Net Income 1.55B 2.39B 1.80B 2.08B 2.51B
EPS (Diluted) 3.52 5.45 4.02 4.61 5.35
Gross Profit 17.37B 17.09B 16.54B 14.67B 13.46B
Operating Income 3.91B 4.40B 4.15B 3.21B 3.66B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 39.07B 32.45B 30.55B 29.86B 24.86B
Total Liabilities 29.16B 22.81B 21.21B 21.30B 16.88B
Shareholders' Equity 9.84B 9.56B 9.26B 8.56B 7.98B
Total Debt 20.99B 15.68B 14.45B 15.08B 11.34B
Cash & Equivalents 1.33B 1.11B 1.14B 1.13B 1.17B
Current Assets 10.08B 9.92B 9.38B 10.02B 7.89B
Current Liabilities 7.42B 6.10B 6.86B 11.57B 10.97B

Puntuaciones de Estrategias

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#291 of 658
33

Actividad Reciente

Entró Contrarian Investing (David Dreman)
Mar 24, 2026